On May 14, 2026 Senti Biosciences Holdings, Inc. (Nasdaq: SNTI) (Senti Bio), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, reported financial results for the first quarter ended March 31, 2026, and provided recent business highlights.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We entered 2026 with a clear focus on advancing SENTI-202 and extending our operational runway while positioning the company for its next phase of clinical development," said Timothy Lu, M.D., Ph.D., Chief Executive Officer and Co-Founder of Senti Bio. "Since the start of the year, we have made meaningful progress across each of these priorities, including a positive regulatory engagement with the FDA on SENTI-202 – a Regenerative Medicine Advanced Therapy (RMAT) designated product – regarding the study design for the planned pivotal trial, execution of a strategic financing agreement that could provide up to $40 million in capital, and continued reductions in operating expenses and cash burn."

Dr. Lu added, "We believe the recent FDA interactions and feedback represent an important milestone for the program and further support the potential of SENTI-202 in relapsed/refractory hematologic malignancies. We remain focused on advancing SENTI-202 efficiently toward the next stage of pivotal development in R/R AML and exploring future combinations with standard of care chemotherapy in newly diagnosed AML patients. We also aim to use our differentiated gene circuit platform to create therapies for additional ex vivo and in vivo CAR therapies."

Recent Business Highlights

SENTI-202 Program Update

Senti Bio concluded a Type B Initial Comprehensive Multidisciplinary RMAT meeting with FDA. Based on the positive outcome of this meeting, Senti Bio has finalized its pivotal clinical and chemistry, manufacturing and controls (CMC) strategy for SENTI-202, which includes a single-arm, multi-center pivotal trial to support registration in R/R AML with SENTI-202 administered after LD chemotherapy. The Company believes the FDA interaction supports continued advancement of SENTI-202 and provides important clarity around a potential registrational development strategy.

In addition, Senti announced that it identified a specific Donor X attribute that correlates with efficacy of SENTI-202, with 50% (7/14) of the patients achieving a composite CR (cCR) when they received any SENTI-202 doses manufactured from Donor X-characteristic derived NK cells in Cycle 1. The Donor X attribute is found in ~50% of adult donors, is independent of HLA or KIR matching, and will be used in all future SENTI-202 manufacturing, thus supporting SENTI-202’s allogeneic off-the-shelf usage. Senti Bio also announced that SENTI-202 continues to achieve durable MRD-negative responses in the full 22 patient Phase 1 trial that compares favorably with current FDA approved therapies for R/R AML.

Additional details can be found on Senti Bio’s website.

Strategic Financing Agreement

In April 2026, Senti Bio entered into a securities purchase agreement with an affiliate of Celadon Partners SPV 24, pursuant to which Senti Biosciences, Inc., the Company’s wholly owned subsidiary, may issue up to $40 million aggregate principal amount of senior secured convertible notes in up to two tranches.

The financing includes:

An initial $10 million tranche, expected to close in May subject to specified closing conditions;
An additional tranche of up to $30 million, subject to investor election and additional conditions; and
Future potential contingent value rights tied to regulatory and commercial milestones for SENTI-202 that could provide up to an aggregate of $60 million in additional value to stockholders.
The Company expects to use proceeds from the financing to support general corporate purposes and advance clinical and manufacturing activities for SENTI-202.

Operational and Financial Restructuring Progress

During the first quarter, Senti Bio completed amendments to its Alameda lease and related GeneFab sublease arrangements, significantly reducing future lease obligations and streamlining operations.

These actions contributed to a $6.9 million gain from lease modification during the quarter and are expected to further reduce the Company’s ongoing operating expense profile.

First Quarter 2026 Financial Results

Cash Position: Cash and cash equivalents were $8.9 million as of March 31, 2026, compared to $16.4 million as of December 31, 2025.
Research and Development Expenses: Research and development expenses were $5.3 million for the first quarter of 2026, compared to $9.3 million for the same period in 2025. The decrease was primarily driven by lower external services and supplies costs.
General and Administrative Expenses: General and administrative expenses were $6.2 million for the first quarter of 2026, compared to $7.1 million for the same period in 2025. The decrease was primarily driven by lower external services and supplies costs.
Net Loss: Net loss was $4.2 million, or $0.14 per basic and diluted share, for the first quarter of 2026, compared to a net loss of $14.1 million, or $1.41 per basic and diluted share, for the first quarter of 2025. Net loss for the three months ended March 31, 2026 included non-cash stock-based compensation expense of $1.3 million, offset by a non-recurring $6.9 million gain on lease modification.
Cash Burn: Net cash used in operating activities was $7.5 million during the first quarter of 2026, compared to $14.1 million during the same period in 2025, reflecting continued operational discipline and restructuring actions.
About SENTI-202

SENTI-202 is the first Logic Gated off-the-shelf CAR-NK cell therapy product candidate designed to selectively target and eliminate CD33 and/or FLT3 expressing hematologic malignancies, such as AML and myelodysplastic syndrome (MDS), while sparing healthy bone marrow cells. SENTI-202 has three main components. First, SENTI-202 contains an OR GATE, which is an activating CAR that recognizes and kills CD33 and FLT3 expressing cells. By targeting either or both of these antigens, SENTI-202 is designed to effectively kill both leukemic blasts (that largely express CD33) and leukemic stem cells (that predominantly express FLT3), which constitute a difficult-to-eradicate reservoir of AML disease. Second, SENTI-202 contains a NOT GATE, which is an inhibitory CAR that is designed to recognize EMCN selectively expressed on healthy hematopoietic stem and progenitor cells and protect those healthy cells from being killed even if they express CD33 and/or FLT3, thus potentially widening the therapeutic window. Third, SENTI-202 contains calibrated-release IL-15, which is designed to significantly increase cell persistence, expansion and activity of both the CAR-NK cells and host immune cells. The NK cells used to construct SENTI-202 are sourced from selected healthy adult donors, manufactured, cryopreserved and available off-the-shelf for use as needed. Senti Bio is currently enrolling adult patients with R/R CD33 and/or FLT3 expressing heme malignancies in a Phase 1 clinical trial for SENTI-202, which can be a potential first-in-class allogeneic treatment for AML/MDS patients.

The U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) and Regenerative Medicine Advanced Therapy (RMAT) designation to SENTI-202 for the treatment of relapsed/refractory hematologic malignancies including AML.

(Press release, Senti Biosciences, MAY 14, 2026, View Source [SID1234665742])

On May 14, 2026 Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, reported positive preclinical findings from an ongoing translational immuno-oncology study evaluating its lead candidate, SIL204, in human KRAS-mutated pancreatic cancer cells. The study demonstrated a statistically significant increase in surface expression of major histocompatibility complex class I (MHC-I), also known as HLA-ABC, following treatment with SIL204 in human pancreatic cancer cells harboring the KRAS G12R mutation, as measured by flow cytometry.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"These findings are particularly encouraging because they suggest SIL204 may influence biological pathways involved in the tumors evading the immune cells which are supposed to protect against the tumors, in addition to its previously demonstrated direct anti-tumor activity," said Ilan Hadar, Chairman and Chief Executive Officer of Silexion Therapeutics. "Checkpoint inhibitors have historically shown limited efficacy in pancreatic cancer in part because T cells often fail to adequately recognize these tumors. We believe the observed increase in MHC-I expression further supports an additional positive role of SIL204 in the area of immunotherapy which could facilitate positive outcomes in the treatment of pancreatic cancer."

MHC-I is essential for enabling cytotoxic T cells to recognize and attack tumor cells. Loss or suppression of MHC-I expression is widely recognized as a key mechanism by which tumors evade immune detection and resist immune-mediated destruction. Research has shown that oncogenic KRAS signaling contributes to immune evasion through suppression of antigen presentation and impairment of T-cell recognition pathways in pancreatic cancer and other KRAS-driven tumors.

Pancreatic cancer remains among the most immunologically resistant solid tumors and has historically demonstrated limited responsiveness to immune checkpoint inhibitor therapies such as anti-PD-1 agents, including pembrolizumab (Keytruda), outside of select biomarker-defined patient populations. By increasing MHC-I expression, SIL204 may help restore immune visibility of KRAS-mutated tumor cells, potentially supporting future therapeutic strategies designed to enhance responsiveness to PD-1/PD-L1 blockade.

Published research has increasingly highlighted the relationship between KRAS signaling, antigen presentation, and immune checkpoint resistance, with multiple recent studies suggesting that reversing KRAS-associated immune suppression may improve immune-mediated anti-tumor activity.

(Press release, Silexion Therapeutics, MAY 14, 2026, View Source [SID1234665741])

On May 14, 2026 Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, reported financial results for the three months ended March 31, 2026, and provided a corporate update highlighting continued execution across its SkinJect and Teverelix development programs.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

During the first quarter of 2026, Medicus continued to advance its transition into a diversified clinical-stage biotechnology company with active development programs in dermatologic oncology and urology/oncology, while replenishing its balance sheet through multiple capital market initiatives.

The Company recently reported positive, decision grade, expanded dataset findings from its Phase 2 SKNJCT-003 study evaluating SkinJect Doxorubicin Microneedle Array (D-MNA) for the treatment of nodular basal cell carcinoma (BCC), including evidence of positive dose response and registrational grade clearance rates in the 200-µg treatment cohort.

In parallel, Medicus advanced Teverelix, its next-generation long-acting GnRH antagonist acquired through the acquisition of Antev Limited, with Food and Drug Administration (FDA) clearance to initiate a Phase 2b dose optimization study in advanced prostate cancer and submission of an optimized Phase 2 protocol in acute urinary retention recurrence prevention.

Management Commentary:

"During the first quarter of 2026, Medicus continued to execute on its transformation into a diversified clinical-stage biotechnology company, highlighted by expanded positive Phase 2 SkinJect data, advancement of Teverelix into additional clinical development pathways, and continued expansion of our regulatory and strategic initiatives," stated Dr. Raza Bokhari, Medicus’ Executive Chairman & CEO. "We believe the growing strength of our clinical datasets, combined with expanded financing flexibility and continued development of AI-enabled clinical capabilities, positions the Company to pursue multiple value-driving milestones in dermatologic oncology, prostate cancer, acute urinary retention, and rare disease indications throughout 2026 and beyond."

First Quarter 2026 and Recent Corporate Highlights

SkinJect Platform (Dermatology / Oncology / Rare Disease)

SkinJect, a novel localized immuno-oncology precision product focused on non-melanoma skin diseases, especially basal cell carcinoma (BCC) and Gorlin Syndrome, a rare autosomal dominant disease also called nevoid BCC syndrome, collectively representing a ~$2 billion market opportunity.

In the first quarter 2026, the Company made the following noteworthy advances in the SkinJect program:

Reported positive topline and expanded dataset findings from the Phase 2 SKNJCT-003 clinical study evaluating D-MNA for nodular basal cell carcinoma.
Expanded analysis demonstrated positive dose-response trends and clinically meaningful clearance activity in the 200-µg treatment cohort.
Company believes the dataset supports continued FDA engagement regarding potential registrational development pathways.
Completed enrollment of 90 patients in the U.S.-based Phase 2 SKNJCT-003 study.
Continued expansion activities for the SKNJCT-004 UAE-based clinical study evaluating SkinJect in additional geographic markets.
Submitted an Orphan Drug Designation application to the FDA for SkinJect in Gorlin Syndrome patients.
Continued collaboration with the Gorlin Syndrome Alliance to support compassionate access and expanded access development initiatives.
Teverelix Platform (Prostate + Women’s Health)

Teverelix, a next generation GnRH antagonist, is a first-in-market product for cardiovascular high-risk advanced prostate cancer patients and patients with acute urinary retention relapse (AURr) episodes due to enlarged prostate, collectively representing an ~$6 billion market opportunity.

In the first quarter 2026, the Company made the following noteworthy advances in the Teverelix program:

FDA provided "study may proceed" clearance for the Company’s Phase 2b dose optimization study evaluating Teverelix in advanced prostate cancer.
Submitted optimized Phase 2 protocol to the FDA for prevention of recurrent acute urinary retention in men with benign prostatic hyperplasia.
Presented additional clinical data relating to Teverelix at the American Association of Clinical Endocrinology (AACE) Annual Meeting 2026.
Successfully amended the LifeArc licensing agreement, reducing the royalty rate payable on worldwide net sales from approximately 4% to 2%.
Other Strategic and Corporate Initiatives:

In the first quarter 2026, the Company continued to make progress in other relevant strategic and corporate initiatives, some of which are highlighted below:

Continued development of the Company’s AI-enabled clinical development collaboration with Reliant AI.
Expanded ATM financing capacity from up to approximately $15.3 million to up to $50 million subsequent to quarter end.
Continued evaluation of additional strategic acquisition and partnering opportunities aligned with the Company’s multi-strategy development platform.
Financial Highlights (Q1 2026):

During the first quarter of 2026, the Company continued to replenish its capital position through utilization of its at-the-market ("ATM") facility and Standby Equity Purchase Agreement ("SEPA"), securing approximately $10 million in aggregate gross financing proceeds during the quarter. Subsequent to quarter end, the Company also expanded its ATM facility from up to approximately $15.3 million to up to $50 million.

The Company operates as a clinical-stage enterprise and expects to incur operating losses for the foreseeable future. As disclosed in the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, substantial doubt exists regarding the Company’s ability to continue as a going concern without additional financing. However, management believes the Company continues to have access to additional capital resources through public and private equity offerings, debt financings, strategic collaborations, licensing arrangements, and other financing initiatives. Financial results of the Company for the quarter ended March 31, 2026, include:

Cash and cash equivalents: $6.4 million as of March 31, 2026 (vs. $4.0 million as of March 31, 2025)
Operating expenses: $8.6 million (vs. $5.1 million in Q1 2025)
General & administrative: $5.9 million (vs. $3.1 million in Q1 2025)
Research & development: $2.7 million (vs. $2.0 million in Q1 2025)
Net loss: $9.0 million (vs. $5.1 million in Q1 2025)
Loss from operations: $8.6 million (vs. $5.1 million in Q1 2025)
Net loss per share: $0.31 (vs. $0.42 in Q1 2025)
The Company’s complete unaudited financial statements and results of operations for the quarter ended March 31, 2026 are included in its Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 14, 2026.

Expected Upcoming Catalysts in 2026

The Company expects 2026 to remain a catalyst-rich year with multiple anticipated milestones, including:

End-of-Phase 2 FDA meeting (SkinJect) to define registrational pathway
Potential registrational trial design alignment under 505(b)(2) framework
Advancement of Gorlin Syndrome Orphan Drug designation, Registrational grade IND and Pediatrics Rare Disease Voucher Program
Continued evaluation of HelixNano-enabled platform expansion opportunities
Expansion of Teverelix into women’s health (endometriosis) using genomics-enabled clinical strategy
Progression of agentic AI-driven clinical development platform with Reliant AI
Ongoing strategic partnering discussions across both core programs, Skinject and Teverelix
Potential expansion of strategic collaborations and licensing discussions
The Company believes its current financing infrastructure, including the expanded ATM facility and existing capital market access, provides flexibility to support ongoing operations and advancement of its clinical development programs.

(Press release, Skinject, MAY 14, 2026, View Source [SID1234665740])

On May 14, 2026 Degron Therapeutics ("Degron"), a clinical-stage biotechnology company advancing molecular glue degrader (MGD) medicines targeting previously undruggable or insufficiently drugged proteins, reported the closing of a $40 million Series A Extension. The round was led by LAPAM CAPITAL. Additional investors include GTJA Investment Group, Fortune Capital, CSPC & Growth, ApicHope, GF Xinde, CASSTAR, Kinghall Ventures, and GAGE Capital. This brings Degron’s total capital raised to $95 million.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The financing will advance Degron’s lead program, DEG6498—a first-in-class HuR (Human antigen R) molecular glue degrader—which entered the clinic in late 2025 with first patient dosed in November. The program, which targets a previously undruggable RNA-binding protein with key roles in driving cancer, inflammation, and metabolic disorders, is currently in dose escalation in a Phase 1 study in patients with advanced solid tumors.

"We are thrilled to welcome this distinguished group of investors who share our vision for transforming the treatment of serious diseases with high unmet need through our innovative MGD platform," said Lily Zou, Ph.D., co-founder and CEO of Degron Therapeutics. "This financing will support the continued advancement of our clinical-stage and preclinical pipeline and further strengthen our technology platform. The strong interest from leading healthcare investors underscores confidence in our approach to developing novel MGDs. With our first-in-class HuR program now advancing in the clinic and two additional immunology programs approaching pre-clinical development, we are making significant progress toward our goal of delivering breakthrough therapies to improve patients’ lives."

Proceeds from this financing will support the continued clinical development of DEG6498, advancing immunology programs to development candidate stage in 2026, and the ongoing expansion of the company’s proprietary GlueXplorer platform to generate potential first-in-class and best-in-disease molecular glue degrader candidates.

"We are pleased to lead this financing round for Degron. Targeted protein degradation remains a key focus for us, and Degron’s proprietary molecular glue platform, built on deep expertise and a strong data foundation, demonstrates robust capabilities in discovering novel targets and compounds, including for historically undruggable targets," said Mr. Zhihua Yu, Chairman of Lapam Capital, which led the financing. "We are impressed by the team’s strengths across R&D, translational development, and business development. With this financing, we believe Degron is well-positioned to advance its pipeline efficiently and generate compelling clinical data to benefit patients."

Founded in 2021 by ShanghaiTech University professor and company co-founder Yong Cang, Ph.D., Degron Therapeutics built a de novo molecular glue degrader discovery platform, GlueXplorer. The company has created more than 10,000 structurally differentiated MGD compounds across more than 150 novel non-IMiDs cores, combined with multiple complementary screening and validation approaches. The platform has enabled Degron to build a pipeline of programs targeting important disease-causing proteins that have historically been inaccessible to conventional small-molecule drugs.

In addition to advancing its internal pipeline, Degron continues to partner with leading pharmaceutical and biotechnology companies to expand MGD R&D across multiple therapeutic areas, including its ongoing collaboration with Takeda.

About DEG6498

DEG6498 is a potent, orally bioavailable small-molecule molecular glue degrader that induces the interaction between the E3 ubiquitin ligase component cereblon (CRBN) and the RNA-binding protein Human antigen R (HuR), leading to the targeted degradation of HuR protein. DEG6498 is being evaluated in a Phase 1 first-in-human study (NCT07244835 / CTR20254261) in patients with advanced solid tumors.

(Press release, Shanghai Degron Therapeutics, MAY 14, 2026, View Source [SID1234665739])

On May 14, 2026 Ontada, a McKesson business dedicated to real-world oncology data and insights, reported that it will present new real‑world research and introduce ON.Journey, a new oncology data solution, at ISPOR 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To continue advancing impactful real-world oncology research, Ontada is launching ON.Journey, a new portfolio of off-the-shelf, longitudinal oncology datasets. Built using oncology-specific artificial intelligence and natural language processing applied to structured and unstructured clinical data from Ontada’s proprietary dataset of electronic medical records from community oncology practices, ON.Journey enables medical affairs, health economics and outcomes research (HEOR), epidemiology, and real-world evidence teams to generate rich clinical insights with speed. With claims data natively integrated, ON.Journey allows teams to analyze treatment utilization alongside clinical outcomes—without the need for custom integration or third-party linkage.

"ON.Journey reflects our focus on delivering data solutions that help life sciences teams generate evidence with greater speed and consistency," said Christine Davis, president of Ontada. "It enables access to research-grade oncology data, supporting evolving needs across the lifecycle."

Ontada will present 12 posters at ISPOR 2026, including four that examine real-world treatment adoption, outcomes and patterns of care across community oncology populations.

"Real‑world evidence provides important insight into how cancer care is delivered," said Jessica K. Paulus, ScD, vice president, Real-World Research for Ontada. "The studies presented at ISPOR reflect our commitment to using high‑quality community oncology data to inform evidence generation and deepen understanding of care delivered in real world clinical practice settings."

Highlights of Ontada’s presence at ISPOR include:

1. Poster #HSD11: Improving Real-World Adoption of HER2-Low Therapies Through Targeted Educational Initiatives

Monday, May 18, 10:30 a.m. – 1:30 p.m. EDT
This observational study and educational initiative evaluates the use of evidence‑based educational outreach in supporting adoption of updated treatment guidelines for HER2‑low therapies.
2. Poster #MSR66: Integrating Generative Artificial Intelligence (AI) into Biostatistical Workflows for Trial Emulation: A Framework to Accelerate Real-World Evidence Generation

Monday, May 18, 4:00 p.m. – 7:00 p.m. EDT
This research outlines a framework for applying generative AI to trial‑emulation workflows to support more scalable and reproducible real‑world evidence generation.
3. Poster # RWD54: Evolution of Homologous Recombination Repair (HRR) Genetic Testing by Race Among Patients with Metastatic Prostate Cancer (mPC) in a Large Community Oncology Setting in the US, 2015 – 2024

Monday, May 18, 4:00 p.m. – 7:00 p.m. EDT
This retrospective, observational analysis uses structured electronic health record data to describe HRR genetic testing patterns by race among patients with metastatic prostate cancer.
4. Poster # HSD112: Real-World Patterns of Homologous Recombination Repair Testing of Patients with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) in the US Community Oncology Setting

Wednesday, May 20, 9:00 a.m. – 11:30 a.m. EDT
This retrospective, observational cohort study examines real-world patterns of HRR genetic testing among patients, highlighting gaps in testing during earlier stages of advanced disease.
Visit the Ontada Booth (#410) at the Pennsylvania Convention Center from May 18-20 to learn more about ON.Journey and Ontada research and data capabilities.

(Press release, Ontada, MAY 14, 2026, View Source [SID1234665738])